AbbVie announces opening of facility in Singapore

AbbVie announced this week that the small molecule active pharmaceutical ingredient (API) facility constructed at its Singapore manufacturing site is now open.

The new facility will enable the advancement of AbbVie’s oncology and women’s health portfolio.

"Our goal as AbbVie is to assure patients around the world have access to new and innovative medicines when they need them and where they need them," AbbVie SVP of Operations Azita Saluki-Gerhardt said. "Today, with the opening of the first phase of our Singapore facility, we will further strengthen our manufacturing capabilities and continue to enhance our support of AbbVie's pipeline in the therapeutic areas of oncology and women's health for patients around the world."

AbbVie Site Director Marc O’Donoghue spoke at the new facility’s opening ceremony.

"Singapore is recognized as a leader in the biopharmaceutical industry and AbbVie is excited to open its facility and begin operations,” he said. “Singapore has a robust infrastructure, a highly educated and skilled workforce and provides a supportive environment for manufacturing. Our presence in Singapore establishes AbbVie's footprint in Asia and provides geographic balance in AbbVie's manufacturing network to ensure continuity of supply."

The facility, located in Tuas Biomedical Park, is 120,000 square meters.